A high-profile analyst questioned the company's recent FDA approval.
Investors are increasingly optimistic about the company.
Much like gold prices, the gold miner is on the up-and-up.
Investors in their later years might want to give these income payers a closer look.
A 273% year-to-date return has this solar stock trading at an all-time high.
Sometimes the best income stocks are the ones that go unnoticed.
Investors seeking income might want to give a hard look at this oil supermajor and leading pulp and paper manufacturer.
What's the true cost of car ownership? This data can help provide insight.
Energy-efficient roofing materials just might be the industrial application U.S. Silica shareholders have been waiting for.
These stocks could help take your portfolio to the next level.
Comments from the U.S. central bank pushed gold prices to nearly $1,400 per ounce.
The business suspended its dividend. While that's not exactly a surprising move, it highlights the sour financial position of the ethanol leader.
The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.
Investors have had to withstand above-average volatility with these two stocks in recent years, but better days are on the horizon.
A new day, a new batch of promising interim data from an early-stage clinical study.
The lithium producer has big growth plans, but the renewable power asset manager has ambitions of its own.
The stock soared to its highest level in over 10 years on encouraging, early-stage clinical results.
Investors just received some bad news about the company's lead drug candidate.
The new materials science company is eager to deliver consistent performance -- and a 6% annual dividend yield -- courtesy of its far-reaching product portfolio.
The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?